Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2025 Earnings Guidance

by · The Markets Daily

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.950-5.350 for the period, compared to the consensus earnings per share estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Stock Up 1.3 %

Shares of Halozyme Therapeutics stock opened at $51.19 on Wednesday. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53. The stock has a market capitalization of $6.51 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 0.44 and a beta of 1.24. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The business’s 50 day simple moving average is $50.10 and its 200-day simple moving average is $54.00.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a report on Monday, December 30th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, JMP Securities increased their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $61.11.

Check Out Our Latest Stock Report on HALO

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also